HOME     SUBSCRIBERS     TRADE     PRODUCTS & SERVICES    
About Sharenet
Enter any share name or code:    

09-Nov-2018
(Official Notice)
Ascendis is pleased to advise shareholders that all the ordinary and special resolutions set out in the notice of Annual General Meeting, held on 8 November 2018, were passed by the requisite number of ordinary shareholders. Ascendis has 489 469 959 ordinary shares in issue of which 372 159 795 shares were voted at the Annual General Meeting, representing 76.03%.

12-Oct-2018
(Official Notice)
Shareholders are hereby notified that, in accordance with the JSE Listings Requirements, the company?s annual compliance report in terms of section 13G(2) of the Broad-Based Black Economic Empowerment Act 53 of 2003 (read with the Broad-Based Black Economic Empowerment Amendment Act 46 of 2013), is available on the company?s website: https://ascendishealth.com/about- us/governance/transformation/
03-Oct-2018
(Official Notice)
Ascendis shareholders (?Shareholders?) are advised that the Integrated Annual Report for the year ended 30 June 2018, including summarised consolidated financial statements for the same period and the Notice of Annual General Meeting, have been posted to Shareholders.



Copies of the Annual General Meeting notice, the summarised audited financial statements and the complete annual financial statements as at 30 June 2018, are available on the Company?s website with effect from today, Wednesday, 03 October 2018 (https://ascendishealth.com/investor-relations /integrated-reports) or alternatively may be requested:

- from the Company?s registered office: 31 Georgian Crescent East, Bryanston, Gauteng, 2191; or

- by email: info@ascendishealth.com



No change statement

Neither the audited annual financial statements referred to herein nor the audit report contain any modifications to the audited results published on SENS on 25 September 2018.



AGM notice

Shareholders are advised that the Company?s sixth Annual General Meeting has been convened for 09:00 on Thursday, 08 November 2018, at Ground Floor, Ascendis building, 31 Georgian Crescent East, Bryanston, Gauteng, 2191, to transact the business stated in the Notice of the Annual General Meeting. 2018

*Record date for determining those shareholders entitled to receive the notice of AGM Friday, 21 September

*Last day to trade in order to be eligible to participate in, and vote at the AGMTuesday, 30 October

*Record date (for voting purposes at the AGM) Friday, 2 November



Participation in the Annual General Meeting will also be facilitated by webcasting and the relevant details appear in the Notice of the Annual General Meeting.
02-Oct-2018
(Official Notice)
The board of directors of Ascendis is pleased to announce the appointment of Mr Johannes George Sebulela as an independent non-executive director with effect from 2 October 2018.







25-Sep-2018
(C)
Revenue for the year increased to R7.737 billion (2017: R6.409 billion), gross profit climbed to R3.469 billion (2017: R2.661 billion), operating profit rose to R939.8 million (2017: R734.2 million), profit attributable to owners of the parent lowered to R277.2 million (2017: R283.1 million), while headline earnings per share grew to 104.4 cents per share (2017: 93.8 cents per share).



Dividend

The directors have elected not to declare a final dividend and to retain the cash to settle debt obligations and improve gearing.
25-Sep-2018
(Official Notice)
07-Sep-2018
(Official Notice)
Shareholders are advised that the group?s annual results for the year ended 30 June 2018, which were scheduled to be released on 11 September 2018, will now be released on SENS on 25 September 2018.



The postponement is due to unexpected delays in finalising the annual results following the implementation of a new financial reporting system late in the financial year.



The board and management apologise for the inconvenience caused by the delay in the release of the results and the related investor presentations. The annual results and strategy presentations will now be held in Johannesburg on 25 September 2018 and in Cape Town on 26 September.



Voluntary trading statement for the year ended 30 June 2018



Ascendis shareholders are advised that the group?s earnings for the year ended 30 June 2018 are

anticipated to be within the following ranges:



Continuing Operations

Basic earnings per share

*12 months ended 30 June 2018 - 96.4 ? 102.9 cents

*12 months ended 30 June 2017 reported - 85.9 cents

*% increase - 12% ? 20%



Headline earnings per share

*12 months ended 30 June 2018 - 102.7 ? 109.2 cents

*12 months ended 30 June 2017 reported - 90.8 cents

*% increase - 13% - 20%



Total Operations

Basic earnings per share

*12 months ended 30 June 2018 - 55.7 ? 62.2 cents

*12 months ended 30 June 2017 reported - 68.7 cents

*% (decrease) / increase - (19%) ? (9%)



Headline earnings per share

*12 months ended 30 June 2018 - 74.5 ? 81.0 cents

*12 months ended 30 June 2017 reported - 80.1 cents

*% (decrease) / increase - (7%) - 1%

25-Jun-2018
(Official Notice)
22-May-2018
(Official Notice)
The board of Ascendis announced that the ordinary shares of Ascendis have been approved for inclusion in the list of qualifying equity securities to be traded on A2X with effect from 29 May 2018 (the "A2X listing date").



Ascendis has a primary listing on the JSE and its issued ordinary share capital will be unaffected by its secondary listing on A2X. Ascendis ordinary shares will be available to be traded on both the JSE and A2X from the A2X listing date.



A2X is a licensed stock exchange authorised to provide a secondary listing venue for companies and is regulated by the Financial Sector Conduct Authority in terms of the Financial Markets Act 19 of 2012.
18-Apr-2018
(Official Notice)
Shareholders were notified of the following internal restructurings undertaken by Coast2Coast Capital (Pty) Ltd. (?C2C?), the latter of which will result in a minimal dilution to Mr Gary Shayne?s and Mr Crispian Dillon?s indirect exposure to C2C?s portfolio investments, one of which comprises a 28.96% interest in Ascendis shares:

- an internal restructuring within C2C of Mr Crispian Dillon?s ownership from subsidiary level to holding company level (?the C2C Restructuring?); and

- an allocation of incentives to C2C staff members, in terms of which C2C staff members acquire an interest in C2C (and therefore exposure to Ascendis shares, amongst other investments held by C2C) (?the C2C Incentives?).



The C2C Restructuring will not, in the absence of the C2C Incentives, result in any change in Mr Crispian Dillion?s or Mr Gary Shayne?s effective interest in C2C and therefore in Ascendis shares.



The implementation of the C2C Incentives will result in a minimal dilution of Mr Gary Shayne?s and Mr Crispian Dillon?s interest in C2C (and therefore, their indirect effective interest in Ascendis shares), as follows:

- Mr Crispian Dillon?s indirect interest in Ascendis shares will be diluted by 0.12% (i.e. from 4.35% to 4.23%); and

- Mr Gary Shayne?s indirect interest in Ascendis shares will be diluted by 0.69% (i.e. from 24.67% to 23.98%).



There will be no movement or dealing in Ascendis shares by C2C as a result of the implementation of the C2C Restructuring and/or the C2C Incentives and therefore the aggregate exposure by C2C to Ascendis will remain unchanged at 28.96%.
01-Mar-2018
(C)
Revenue for the period increased to R3.962 billion (2016: R3.110 billion), gross profit jumped to R1.750 billion (2016: R1.324 billion), operating profit rose to R476.6 million (2016: R354.4 million), profit attributable to owners of the parent was higher at R216.5 million (2016: R173.5 million), while headline earnings per share from continuing operations rose to 53.4 cents per share (2016: 42.2 cents per share).



Dividend

The directors have elected not to declare an interim dividend and to retain cash to settle debt obligations.



Company outlook

The group will continue to pursue organic and more focused synergistic growth strategies across the South African and international businesses to increase revenue growth and profitability. After synergy benefits realised EBITDA of R19 million in the past six months, the group is targeting to accelerate synergy savings in the next 12 to 18 months, mainly in the South African pharma and Medical Devices businesses. Management is targeting to improve the EBITDA margin to 17% - 18% in the short to medium term. Reducing gearing levels and improving cash generation remain priorities. Projects are underway to optimise inventory levels in the Pharma-Med and Consumer Brands segments and to improve debt collection from private sector and government debtors in Pharma-Med. Operationally the key focus will be on the Scitec turnaround strategy and implementation, extracting synergies from the recent acquisitions of Remedica, Scitec, Sun Wave Pharma and Cipla, effectively driving higher organic growth, while also ensuring an efficient leadership transition following the appointment of the new CEO. A strategic business review has been initiated to create a sustainable market position for Ascendis Health and to accelerate organic growth following the completion of several acquisitions locally and offshore since the company's listing in 2013. The review is expected to be completed late in the 2018 financial year.

27-Feb-2018
(Official Notice)
The board of Ascendis announced the appointment of Thomas Thomsen as chief executive officer (?CEO?) and as an executive director with effect from 1 March 2018.



Thomas (48) will succeed Dr Karsten Wellner (57) who has been the CEO since the founding of the group in 2011. Karsten will work with Thomas over the next four months to ensure a smooth transition. Karsten will stand down as CEO on 1 March 2018 and as a board director on 30 June 2018.
01-Feb-2018
(Official Notice)
31-Jan-2018
(Official Notice)
Ascendis shareholders are hereby advised that the company?s basic earnings, headline earnings and earnings per share for the financial results from continuing operations for the six months ended 31 December 2017 (?the period?) are expected to be more than 20% higher than the previous corresponding period. The normalised earnings and earnings per share are expected to be in the ranges shown below.



The following table outlines the earnings ranges anticipated relative to the comparative period.



Shareholders will note that owing to the 12% increase in the weighted average number of shares during the period, the ?per share? measures reflect a lower percentage increase than the Rand value of earnings.



Continuing Operations

6 months ended 31 December 2017; 6 months ended 31 December 2016 % increase/ (decrease)

*Basic earnings per share (?EPS?) - 52 ? 54 cents; 43 cents; 20% ? 26%

*Headline earnings per share (?HEPS?) - 52 ? 55 cents; 42 cents 24% - 30%



Shareholders are advised that the results for the six months ended 31 December 2017 are scheduled to be released on SENS on 01 March 2018, to be presented to investors in Cape Town on 1 March 2018 and in Johannesburg on 2 March 2018 (refer to www.ascendishealth.com for details on the results presentation). Management will provide details on the performance of recent local and international acquisitions in the investor presentations.
19-Jan-2018
(Official Notice)
The board of directors of the company advised shareholders that Questco Corporate Advisory (Pty) Ltd. has been appointed as the company?s Sponsor, with effect from 15 January 2018.
18-Dec-2017
(Official Notice)
Ascendis shareholders are referred to the finalisation announcement released on the Stock Exchange News Service (?SENS?) of the JSE on 23 November 2017 and the circular to shareholders dated 28 November 2017 relating to an underwritten, renounceable rights offer to raise R750 million (?Rights Offer?) in order to settle EUR50 million of the deferred vendor consideration payment owing to the sellers of Remedica Holdings Ltd. at a discount in advance of the original due date.



The Rights Offer consisted of an offer for subscription of 37 501 366 new Ascendis ordinary shares (?Rights Offer Shares?) in the ratio of 8.365 Rights Offer Shares for every 100 ordinary shares held on the record date of the Rights Offer, at a subscription price of R20.00 per Rights Offer Share. The subscription price of R20.00 per Rights Offer Share was at a premium of 4.6% to the 30 day volume weighted traded average price (?VWAP?) on Tuesday, 31 October 2017 of R19.12, being the date immediately prior to the voluntary announcement of the Rights Offer released on SENS. The Rights Offer was fully underwritten to the extent of R750 million by a wholly owned subsidiary of the major shareholder, Coast2Coast Capital (Pty) Ltd. (?Coast2Coast? or ?the Underwriter?).



Underwriting

In terms of its pro rata entitlement as a shareholder of Ascendis, Coast2Coast was entitled to subscribe for 9 903 767 Rights Offer Shares. For ease of administration, Coast2Coast has elected to subscribe for this entitlement as part of its underwriting obligation post the closing of the Rights Offer, along with Rights Offer Shares not taken up by other shareholders. Effectively, Coast2Coast has taken up its rights in full and subscribed for a further 27 437 020 Rights Offer Shares, comprising 73% of the Rights Offer, in terms of its underwriting commitment.
11-Dec-2017
(Official Notice)
Notice is hereby given that the company?s updated annual compliance report in terms of section 13G(2) of the Act has been published and is available on the company?s website at www.ascendishealth.com
28-Nov-2017
(Official Notice)
23-Nov-2017
(Official Notice)
Shareholders of Ascendis (?Shareholders?) are referred to the rights offer declaration announcement released on the Stock Exchange News Service (?SENS?) of the JSE Ltd. (?JSE?) on Tuesday, 21 November 2017 (?Declaration Announcement?) in respect of the fully underwritten renounceable rights offer of approximately R750 million (?Rights Offer?) in terms of which Ascendis will offer a total of 37 501 366 new ordinary shares of no par value (?Rights Offer Shares?) at a price of R20.00 per Rights Offer Share in the ratio of 8.36500 Rights Offer Shares for every 100 existing shares held on the record date for the Rights Offer, being Friday, 1 December 2017.



Shareholders are advised that the terms of the Rights Offer have now been finalised and all conditions precedent to the Rights Offer have been fulfilled, accordingly the Rights Offer may now be implemented.



The salient dates and times of the Rights Offer will be the same as those published in the Declaration Announcement. Shareholders may commence trading the Rights Offer Shares on Wednesday, 13 December 2017.



Further details of the Rights Offer (including the form of instruction) will be set out in the circular to Shareholders (?Circular?) and will be available on the Ascendis website (www.ascendishealth.com) on Tuesday, 28 November 2017. The Circular will be posted to certificated Shareholders and to those dematerialised Shareholders who have requested to receive copies of circulars on Thursday, 30 November 2017.
21-Nov-2017
(Official Notice)
13-Nov-2017
(Official Notice)
10-Nov-2017
(Official Notice)
Ascendis shareholders are advised that at the Fifth Annual General Meeting of members held on Thursday, 9th November 2017, all the ordinary and special resolutions as proposed in the Notice of the Annual General Meeting were approved by the requisite majority of members.
01-Nov-2017
(Official Notice)
Shareholders are advised that the board of directors of Ascendis (the ?board?) has in-principle resolved, subject to further finalisation, to pursue an underwritten renounceable rights offer (?Rights Offer?) to shareholders.



The board intends to pursue the proposed Rights Offer on the following indicative terms and conditions:

- company intends to raise approximately R750 million;

- It is anticipated that the Rights Offer shares will be offered at a premium to the current market price, as the board believes the current market price is not reflective of the company?s intrinsic value; and

- The company?s largest shareholder, Coast2Coast Capital (Pty) Ltd. (?Coast2Coast?) is supportive of the capital raising and will underwrite the proposed Rights Offer to the extent of R750 million;



The proceeds of the proposed Rights Offer will be used to settle a significant portion of the outstanding deferred vendor consideration payments which will be settled at a discount to the outstanding value.



The final terms and conditions of the underwriting arrangement and pricing of the Rights Offer are in the process of being finalised and will be communicated to shareholders in due course.
31-Oct-2017
(Official Notice)
Ascendis shareholders are advised that Mr Cliff Sampson, Managing Director of Ascendis? South African operations, will reach his retirement date on 30 June 2018 in accordance with the terms of his employment contract.



As a consequence of the conclusion of his employment contract, Mr Sampson will retire from the board of directors of Ascendis (the ?Board?) as an executive director and as managing director of the Ascendis South African operations on 30 June 2018. Mr Sampson has made himself available post his retirement to ensure a smooth and successful handover.



The Board is in the process of securing a replacement executive and will manage the process to ensure a phased hand-over of accountabilities and responsibilities. This process will take into account the Company?s transformation principles. The South African division is well supported by a strong executive team in the Phyto-Vet, Pharma, Medical Devices and Consumer Brands business units and has invested heavily in its human capital over the past 4 years.
16-Oct-2017
(Official Notice)
In accordance with paragraph 16.20 (g) and Appendix 1 to Section 11 of the JSE Listing Requirements, notice is hereby given that the Company?s annual compliance report in terms of section 13G(2) of the Act has been published and is available on the Company?s website at www.ascendishealth.com.
29-Sep-2017
(Official Notice)
Ascendis shareholders (?Shareholders?) are advised that the Integrated Annual Report for the year ended 30 June 2017, including summarised consolidated financial statements for the same period and Notice of Annual General Meeting, have been posted to Shareholders and is available on the Company?s website with effect from Friday, 29 September 2017 (www.ascendishealth.com )



Copies of the Annual General Meeting notice, the summarised audited financial statements, and the complete annual financial statements as at 30 June 2017 are available:

*from the Company?s registered office: 31 Georgian Crescent East, Bryanston, Gauteng, 2191; or

*by email: info@ascendishealth.com



No change statement

The annual financial statements referred to herein contain no modification to the audited results that were published on 12 September 2017 on SENS, and in the press on 13 September 2017. Ascendis? results and the annual financial statements have been audited by PricewaterhouseCoopers Inc. whose unqualified a u d i t report is available for inspection at the Company?s registered office.



Notice of annual general meeting

Shareholders are advised that the Company?s fifth Annual General Meeting has been convened for 09:00 on Thursday, 0 9 November 2017, at Block A, Silverwood, Steenberg Office Park, Silverwood Close, Tokai, Cape Town, 7 9 4 5 , to transact the business stated in the Notice of the Annual General Meeting. The voting record date is Friday, 3 November and the last date to trade is Tuesday, 31 October 2017.



Participation in the Annual General Meeting will also be facilitated by webcasting and the relevant details appear in the Notice of the Annual General Meeting.



12-Sep-2017
(C)
Revenue for the year jumped to R6.4 billion (R3.9 billion) whilst operating profit almost doubled to R748.3 million (R383.3 million). Profit attributable to owners shot up to R283.1 million (R158.7 million). In addition, headline earnings per share from continued operations grew to 90.8 cents per share (55.6 cents per share).



Dividend

The directors have elected not to declare a final dividend and to retain cash to fund complementary acquisitions. An interim dividend of 11 cents per share was declared in March 2017.



Company outlook for 2018 financial year

The group will continue to pursue its proven strategy of organic, acquisitive, synergistic and international growth to create shareholder value.



Projects have been initiated to enhance organic growth and EBITDA margins. These include consolidating the medical devices division in South Africa focusing on cost efficiencies across the group, in particular in the sports nutrition businesses, rationalising manufacturing facilities in South Africa and investing in new product development and launches. Management is targeting to improve the EBITDA margin from 17% to 18% over the medium term. Plans are being implemented to maximise free cash generation and reduce gearing levels.



The group's acquisition strategy in 2018 will be focused on buying complementary bolt-on businesses, mainly in the higher growth economies in central and eastern Europe, and South Africa, while targeting fast growing health and care market segments.
31-Aug-2017
(Official Notice)
Ascendis announced the appointment of Thomas Thomsen as the Chief Operating Officer (?COO?) of Ascendis with effect from August 2017. Thomas is based in the United Kingdom and will be primarily responsible for all European operations in terms of their performance and implementing the value creation and integration plans for the international assets of Ascendis. This is particularly important as Ascendis continues to grow its non- South African earnings which currently account for c.60% of total earnings on a consolidated basis.
24-Aug-2017
(Official Notice)
Ascendis shareholders are hereby advised that the Company?s financial results for the twelve months ended 30 June 2017 are expected to be more than 20% higher than the previous corresponding period.



The ranges anticipated against the comparative period are:



Continuing Operations

Basic earnings

*12 months ended 30 June 2017: R342m - R367m

*12 months ended 30 June 2016: R159m

*% increase/decrease: 115% - 131%



Basic earnings per share (?EPS?)

*12 months ended 30 June 2017: 83 - 89 cents

*12 months ended 30 June 2016: 57 cents

*% increase/decrease: 45% - 56%



Headline earnings

*12 months ended 30 June 2017: R353m - R383m

*12 months ended 30 June 2016: R154m

*% increase/decrease: 129% - 149%



Headline earnings per share (?HEPS?)

*12 months ended 30 June 2017: 86 - 93 cents

*12 months ended 30 June 2016: 56 cents

*% increase/decrease: 54% - 66%



Total Operations

*Basic earnings: R270m - R296m (2016: R159m) being an increase of 70% - 86%

*Basic earnings per share (?EPS?): 65 - 72 cents (2016: 57 cents) being an increase of 14% ? 26%

*Headline earnings: R310m - R340m (2016: R154m) being an increase of 101% - 121%

*Headline earnings per share (?HEPS?): 75- 82 cents (2016: 56 cents) being an increase of 34% - 46%



Despite a challenging trading environment, Ascendis is pleased with the overall resilient performance of its diversified business model during the current financial period. The financial information on which this trading statement is based has not been reviewed or reported on by the Company?s auditors. Shareholders are advised that the results for the twelve months ended 30 June 2017 are scheduled to be released on SENS on 12 September 2017, to be presented in Cape Town on 13 September 2017 and in Johannesburg on 14 September 2017.

12-Jun-2017
(Official Notice)
Ascendis shareholders are advised that the Company will be attending a pre closed period briefing with investors on 12 June 2017 and 13 June 2017. An update will be provided during the briefing in the form of a presentation which will be available on the Company?s website from 12:00 on Monday, 12 June 2017. (www.ascendishealth.com/investor-relations/presentations/).
02-Jun-2017
(Official Notice)
Shareholders of Ascendis Health (?Shareholders?) are referred to the announcement released on the Stock Exchange News Service of the JSE Ltd. on 8 March 2017, wherein shareholders were advised that Ascendis Health had entered into two separate agreements in terms of which Ascendis will acquire:

*The core business assets of Sunwave Pharma SRL (?Sunwave?), a distribution company based in Romania, for a total consideration of EUR 16 350 000, from Sunwave; and

*100% of the intellectual property of NHP Natural Health Pharma Ltd. (?NHP Pharma?), a nutraceutical company based in Cyprus, for a total consideration of between EUR 26 100 000 and EUR 49 100 000, depending on the financial performance of the business over the next three years, from NHP Pharma.



The above agreements are collectively referred to as the ?Transactions? for the purposes of this announcement.



Filfilment of all conditions precedent

Shareholders are advised that all conditions precedent pertaining to the Transactions have now been fulfilled or waived, as the case may be, with the payment by Ascendis Health for the Transactions being concluded on 2 June 2017. As such, the Transactions are officially unconditional, thereby resulting in an effective date of 2 June 2017.

01-Jun-2017
(Official Notice)
Shareholders of Ascendis Health (?Shareholders?) are referred to the announcement released on the Stock Exchange News Service of the JSE Limited on 6 March 2017, wherein Shareholders were advised that Ascendis Health had entered into an agreement on 4 March 2017 in terms of which Ascendis will acquire, directly or indirectly, the entire issued share capital of Cipla Agrimed Proprietary Limited and the entire issued share capital of Cipla Vet Proprietary Limited for a consideration of R375 million (with a potential adjustment to reflect a price band of R250 million and R500 million in relation to actual working capital, net debt and earnings before interest, tax, depreciation and amortisation achieved for the period ending 31 March 2017), from Inyanga Trading 386 (Pty) Ltd., a fully owned subsidiary of Cipla Limited India (the ?Transaction?).



Fulfilment of all conditions precedent

Shareholders are advised that all conditions precedent pertaining to the Transaction have now been fulfilled or waived, as the case may be, with the payment by Ascendis Health for the Transaction being concluded on 1 June 2017. As such, the Transactions are officially unconditional, thereby resulting in an effective date of 1 June 2017.
08-Mar-2017
(Official Notice)
Ascendis shareholders (?Shareholders?) are advised that the Company has entered into two separate agreements in terms of which Ascendis will acquire:

* The core business assets of Sunwave Pharma SRL (?Sunwave?), a distribution company based in Romania, for a total consideration of EUR 16,350,000 (the ?Sunwave Purchase Consideration?), from Sunwave. An agreement was entered into with Sunwave on 7 March 2017 (?Sunwave Transaction?); and

* 100% of the intellectual property (?IP?) of NHP Natural Health Pharma Ltd (?NHP Pharma?), a nutraceutical company based in Cyprus, for a total consideration of between EUR26 100 000 and EUR49 100 000, depending on the financial performance of the business over the next three years (the ?NHP Pharma Purchase Consideration?), from NHP Pharma. An agreement was entered into with NHP Pharma on 7 March 2017 (?NHP Pharma Transaction?).



The Sunwave Transaction and the NHP Pharma Transaction are collectively referred to as the ?Proposed Transactions? for the purpose of this announcement. Sunwave is a distributor of complementary and alternative medicines (?CAMS?) and food supplement products in Romania. It is the largest player in the food supplements category and sixth largest player in the broader over-the-counter (?OTC?) category in the country. The company specialises in marketing its products directly to the doctor community, through a sales force of approximately 290 effective and well-trained individuals. NHP Pharma, in collaboration with its third-party suppliers, has developed a vast product portfolio of complementary medicines across nine major therapeutic areas. The efficacy of its products have been further validated through clinical and post-marketing studies. NHP Pharma owns the trademarks and other relevant IP relating to its products, with Sunwave being NHP Pharma?s largest customer. The Proposed Transactions are inter-conditional and, going forward, will be treated as a single business combination in the hands of Ascendis. Ascendis aims to achieve an EBITDA margin of approximately 20% from the Proposed Transactions.
08-Mar-2017
(C)
Revenue for the period increased to R3.110 billion (2015: R1.871 billion), gross profit jumped to R1.324 billion (2015: R813.9 million), operating profit rose to R383.8 million (2015: R245.2 million), profit attributable to owners of the parent was higher at R173.5 million (2015: R131.8 million), while headline earnings per share from continuing operations lowered to 41.39 cents per share (2015: 48.52 cents per share).



Interim dividend declaration

The board of directors has approved an interim gross ordinary dividend of 11 cents per share (2016: 9.50 cents per share).



Outlook

Synergy projects across the European acquisitions of Remedica, Farmalider and Scitec remain the priority while the group is investing in the geographic diversification and new sales channels for Scitec to improve profitability.



Potential acquisitions of platform and bolt-on businesses in South Africa, Europe and emerging markets are currently being evaluated. Funds of approximately R750 million are available for acquisitions in the next 12 months without raising further equity.



Management aims to focus on creating production efficiencies across the pharma manufacturing facilities in South Africa and Europe, launch several export initiatives from South Africa and enter new high growth markets from its three European platform companies. New product development and innovation will continue to be key to driving organic growth in the health and care markets locally and internationally.
06-Mar-2017
(Official Notice)
23-Feb-2017
(Official Notice)
In terms of paragraph 3.4(b) of the JSE Limited?s Listings Requirements, Ascendis shareholders are hereby advised that the Company?s financial results for the six months ended 31 December 2016 are expected to be more than a 20% change from the previous corresponding period.



The table below illustrates the ranges anticipated against the comparative period: 6 months ended 31 December 2016 :

*Normalised Headline Earnings: R298m ? R315m representing an increase of 97% - 109%

*Normalised Headline Earnings per share (?NHEPS?) : 72 - 76 cents representing an increase of 29% - 36%

*Basic Earnings : R166m ? R178m representing an increase of 26% - 35%

*Basic Earnings per share (?EPS?) : 40 - 43 cents representing a decrease of (18)% - (12)%

*Headline Earnings : R166m ? R178m representing an increase of 27% - 36%

*Headline Earnings per share (?HEPS?) : 40 - 43 cents representing a decrease of (18)% - (12)%



Notes:

1. Normalised headline earnings and NHEPS comprise basic earnings adjusted for specific non- trading items and once-off costs. Once off costs for the 6 months ended 31 December 2016 amount to c.R92m, primarily relating to transaction costs, finance and hedging costs for the purchase of Remedica and Scitec as announced on SENS on 26 August 2016 (?Acquisitions?). Accordingly the contributions from the Acquisitions are not consolidated for the full period.

2. The ?per share? measures reflect a lower percentage increase than the earnings numbers due to the change in weighted average number of shares from c. 270m to 414m due to additional shares issued by Ascendis during the course of the six month period ended 31 December 2016 in connection with the Acquisitions.



The financial information on which this trading statement is based has not been reviewed or reported on by the Company?s auditors. Shareholders are advised that the results for the six months ended 31 December 2016 are scheduled to be released on SENS on 8 March 2017 and presented in Cape Town on 8 March 2017 and Johannesburg on 9 March 2017.

11-Nov-2016
(Official Notice)
Shareholders of Ascendis are referred to the directors dealings announcement released on SENS on 1 November 2016 relating to the legal obligation of Coast2Coast Capital (Pty) Ltd. (?Coast2Coast Capital?) to transfer Ascendis shares to effect the redemption of an existing debenture issued by its indirect subsidiary (?Announcement?).



In accordance with section 122(3)(b) of the Companies Act, 71 of 2008 ("the Act"), and section 3.83(b) of the JSE Listing Requirements, holders of ordinary shares in Ascendis are advised that the Ascendis shares referred to in the Announcement were transferred on 11 November 2016, and as such Coast2Coast Holdings (Pty) Ltd. Group?s (?Coast2Coast Holdings?) beneficial interests in the securities of the company amount to 29.79% of the total number of shares in issue.



Ascendis hereby confirms that it has received the required notice from Coast2Coast Holdings in terms of Section 122(1) of the Act. As required in terms of section 122(3) (a) of the Act, Ascendis has filed the required notice with the Takeover Regulation Panel.



11-Nov-2016
(Official Notice)
Ascendis shareholders are advised that at the Fourth Annual General Meeting of members held on Thursday, 10th November 2016, all the ordinary and special resolutions as proposed in the Notice of the Annual General Meeting were approved by the requisite majority of members.
12-Oct-2016
(Official Notice)
Ascendis shareholders (?Shareholders?) are advised that the Integrated Annual Report for the year ended 30 June 2016, including summarised consolidated financial statements for the same period and Notice of Annual General Meeting, have been posted to Shareholders and is available on the Company?s website with effect from Wednesday, 12 October 2016 (www.ascendis.co.za).



Copies of the Annual General Meeting notice, the summarised audited financial statements, and the complete annual financial statements as at 30 June 2016 are available:

- from the Company?s registered office: 22 Sloane Street, Bryanston, Gauteng, 2191; or

- by email: info@ascendis.co.za



No change statement

The annual financial statements referred to herein contain no modification to the audited results that were published on 14 September 2016 on SENS, and in the press on 15 September 2016.



Notice of AGM

Shareholders are advised that the Company?s fourth Annual General Meeting has been convened for 09:00 on Thursday, 10 November 2016, at Block A, Silverwood, Steenberg Office Park, Silverwood Close, Tokai, Cape Town, 7945 , to transact the business stated in the notice of the Annual General Meeting. Participation in the Annual General Meeting will also be facilitated by webcasting and the relevant details appear in the notice of the Annual General Meeting.
14-Sep-2016
(C)
Revenue for the year jumped to R3.9 billion (R2.8 billion). Gross profit was higher at R1.6 billion (R1.2 billion) whilst operating profit grew to R376.5 million (R362.2 million). Profit attributable to owners lowered to R158.7 million (R209.8 million). In addition, headline earnings per share decreased to 55.56 cents per share (79.31 cents per share).



Dividend

The board of directors has approved a final gross ordinary dividend of 12 cents per share. An interim gross dividend of 9.5 cents per share was declared with the release of the interim results for the period ended 31 December 2015. Therefore a total dividend 21.5 cents per share for full 2016 year (19 cents) has been declared. The source of the dividend will be from distributable reserves and paid in cash.



Outlook

The integration of Remedica and Scitec present significant synergy opportunities in shared services, cross-licensing of pharmaceutical dossiers, product manufacturing and new routes to market in Europe and in developing markets.



International acquisitive growth will focus on platform companies for the wellness, medical devices and phyto-vet businesses in Eastern Europe and emerging markets, while seeking bolt-on acquisitions for Remedica and Scitec. In South Africa the group has a strong acquisition pipeline and will seek brands with existing exports or potential to grow exports.



Management will focus on efficiencies and cost control to improve margins in the manufacture of pharma products. New product development and innovation remain key to maintaining Ascendis' competitive advantage in the health and care markets.
07-Sep-2016
(Official Notice)
Ascendis shareholders are hereby advised that the Company?s financial results for the twelve months ended 30 June 2016 are expected to be more than a 20% change from the previous corresponding period.



The table below illustrates the ranges anticipated against the comparative period:

12 months ended 30 June 2016

*Basic Earnings per share (EPS): 54 - 59 cents which represents (33)% - (26)% decrease

*Headline Earnings per share (HEPS): 52 -57 cents which represents (34)% - (28)% decrease



The financial information on which this trading statement is based has not been reviewed or reported on by the Company?s auditors. Shareholders are advised that the results for the twelve months ended 30 June 2016 are scheduled to be released on SENS on 14 September 2016 and presented in Johannesburg on 14 September 2016 and Cape Town on 15 September 2016.

26-Aug-2016
(Official Notice)
Shareholders of Ascendis Health (?Shareholders?) are referred to the announcement released on the Stock Exchange News Service of the JSE Ltd. on 24 May 2016, wherein Shareholders were advised that Ascendis Health had entered into agreements to acquire, directly or indirectly, through two distinct and divisible transactions:

- The entire issued share capital of Remedica Holdings Ltd., a pharmaceutical company based in Cyprus (?Remedica Transaction?); and

- The entire issued share capital of Scitec International S.? r.l., a European sports nutrition company (?Scitec Transaction?); and

the circular to Shareholders dated 12 July 2016, setting out the details of the Remedica Transaction and the Scitec Transaction (together the ?Transactions?), as well as a rights offer and a vendor consideration placing.



Fulfilment of all conditions precedent

Shareholders are advised that all conditions precedent pertaining to the Transactions have now been fulfilled or waived, as the case may be, with the payment by Ascendis Health for the Transactions being concluded on 25 August 2016. As such the Transactions are officially unconditional and have been implemented as of 25 August 2016.
11-Aug-2016
(Official Notice)
Ascendis shareholders are advised that at the general meeting of members held at Block A Silverwood, Steenberg Office Park, Silverwood Close, Tokai, Cape Town, 7945, at 09:00 on Thursday, 11 August 2016, all the ordinary and special resolutions as proposed in the Notice of the General Meeting were approved by the requisite majority of members.



Update on Equity Raise

Ascendis can confirm that as announced on SENS on 8 August 2016, the R1.2 billion rights offer was three times oversubscribed, and the c.R1.5 billion vendor placement was also significantly over subscribed.



08-Aug-2016
(Official Notice)
Ascendis shareholders are referred to the finalisation announcement released on the Stock Exchange News Service of the JSE on 12 July 2016 and the circular to shareholders dated 12 July 2016 relating to an underwritten, renounceable rights offer (?Rights Offer?) to raise up to R1.2 billion. The Rights Offer consisted of an offer of 54 545 454 Ascendis ordinary shares (?Rights Offer Shares?) in the authorised but unissued share capital of Ascendis, in the ratio of 18.25033 Rights Offer Shares for every 100 ordinary shares held on the record date of the Rights Offer, at a subscription price of R22.00 per Rights Offer Share.



Results of the Rights Offer

The directors are pleased to advise that the Rights Offer was significantly oversubscribed, with total support received for over 300% of the Rights Offer value.



Remaining dates and times

* Qualifying dematerialised shareholders? accounts updated and debited by CSDP or broker (in respect of payments for Rights Offer Shares): Monday, 8 August

* Certificates distributed to qualifying certificated shareholders (in respect of the Rights Offer Shares): Monday, 8 August

* Refunds (if any) to qualifying certificated shareholders in respect of unsuccessful excess applications made: Thursday, 11 August

* Qualifying dematerialised shareholders? accounts updated and debited by their CSDP or Broker (in respect of successful excess applications): Thursday, 11 August

* Certificates distributed to qualifying certificated shareholders (in respect of successful excess applications) : Thursday, 11 August
21-Jul-2016
(Official Notice)
Shareholders of Ascendis (?Shareholders?) are referred to the circular issued to Shareholders on 12 July 2016 relating to a General Meeting of Shareholders on 11 August 2016 and an underwritten renounceable rights offer (?Rights Offer?) (the ?Circular?).



With the advent of electronic settlement, and the subsequent impact on electronic corporate actions in the South African market, combined with the JSE Ltd.?s (?JSE?) move to a T+3 settlement cycle, the Listings Requirements of the JSE were amended (?LR Amendments?) to make provision for the treatment of fractions in relation to corporate actions.



The historical treatment of fractions of all securities being rounded up or down based on the standard rounding convention, (i.e. allocations rounded down to the nearest whole number if they are less than 0.5 and rounded up to the nearest whole number if they are equal to or greater than 0.5) has been changed to a singular rounding down principle in terms of the LR Amendments.



The LR Amendments now provide for a cash value of the fraction at the volume weighted average price less 10% on the last day to trade +1 to be paid out to securities holders.As advised by the JSE, the LR Amendments were incorporated into the Circular to Shareholders (with particular reference to the ?Salient Dates and Times of the Rights Offer? on page 22, paragraph 6 on page 25, and in Annexure 2 of the Circular). Subsequent to the posting of the Circular, the JSE has concluded that the LR Amendments do not apply to rights offers and, as such, the references thereto in the Circular should be amended to revert to the historical treatment.



Shareholders should therefore note that, as a result, all allocations with respect to the Rights Offer will be rounded down to the nearest whole number if they are less than 0.5, and rounded up to the nearest whole number if they are equal to or greater than 0.5, and that no cash portion will be payable for any fractional entitlement. Furthermore, Shareholders are to note that this announcement replaces the abovementioned provisions in the Circular.
12-Jul-2016
(Official Notice)
30-Jun-2016
(Official Notice)
10-Jun-2016
(Official Notice)
Ascendis shareholders are referred to the SENS announcement dated 13 November 2015 whereby Ascendis shareholders approved the requisite ordinary resolution to grant Ascendis directors the general authority to issue shares for cash up to a maximum of 15% of its shares in issue as at the date of the general meeting held on 12 November 2015 (?General Meeting?).



Shareholders are advised that Ascendis has cumulatively issued more than 5% of this authority since the date of the General Meeting in order to fund its acquisitive growth objectives, which includes the funding of the non-refundable deposit required for the acquisition of Scitec as detailed in the SENS announcement dated 24 May 2016. Ascendis hereby declares that it has issued a total of 17 422 324 shares for cash since the General Meeting, representing a weighted average discount of 8.06% to the prevailing 30 business day volume weighted average price as at the respective issue dates.
24-May-2016
(Official Notice)
13-Apr-2016
(Official Notice)
Ascendis shareholders are referred to the SENS announcement dated 19 November 2015 advising of Ascendis entering into an agreement with the shareholders of Akacia to acquire 100% of the pharmaceutical business of Akacia (?the Acquisition?), subject to the fulfilment of certain conditions precedent.



The company?s board of directors announced that all outstanding conditions precedents have been fulfilled which accordingly renders the Acquisition unconditional.



Shareholders are advised that the cautionary announcement released on SENS on 14 March 2016 is still in effect as negotiations are ongoing and accordingly shareholders must continue to exercise caution when dealing in the company?s securities until a full announcement is made.
14-Mar-2016
(Official Notice)
Shareholders are advised that Ascendis has entered into negotiations, which, if successfully concluded may have a material effect on the price of the company?s securities. Accordingly, shareholders are advised to exercise caution when dealing in the company?s securities until a full announcement is made.
09-Mar-2016
(C)
Revenue grew 40% to R1.9 billion (R1.3 billion) whilst gross profit was 36% higher at R813.9 million (R597.6 million). Operating profit jumped 52% to R245.2 million (R161.0 million). Profit attributable to owners rose to R131.8 million (R88.5 million). Furthermore, headline earnings per share from continuing operations increased to 48.52 cents per share (35.49 cents per share).



Interim dividend declaration

The board of directors has approved an interim gross ordinary dividend of 9.50 cents per share (2015: 8 cents per share).



Outlook

Following on from a period of consolidation of its operations in South Africa, management will continue to focus on international acquisitive growth to further improve its hard currency revenue base. Opportunities are currently being evaluated to acquire platform companies for all three divisions in Australia and Europe. In South Africa, the group is in negotiations for further bolt-on acquisitions across all divisions.



The finalisation and integration of the Akacia acquisition for the Pharma division will enhance operating margins and open up new distribution channels for Ascendis Pharma. Management is focusing on extracting synergies across the three pharma manufacturing sites in Johannesburg and Madrid, and on increasing in-house and domestic production to de-risk the business from Rand volatility and to improve the value chain.



Operationally the group's priorities are to improve margins through strict cost control and focus on efficiencies, finalise the Sports Nutrition joint production project, open new routes to market in South Africa, accelerate growth in export sales and continue new product development and innovation.



In striving to deliver competitive returns to shareholders, the group will pursue its organic, acquisitive and synergistic growth strategies as it develops Ascendis into a global company founded on strong South African health brands.
02-Mar-2016
(Official Notice)
Ascendis shareholders are hereby advised that the Company?s financial results for the six months ended 31 December 2015 are expected to be more than 20% higher than the previous corresponding period. The table below illustrates the ranges anticipated against the comparative period:

Six months ended 31 December 2015 - 31 December six months ended 2014 - % increase

* Normalised Headline Earnings : R146 million ? R154 million - R107 million - 36% ? 44%

* Normalised Headline Earnings per share : 54 ? 57 cents - 43 cents - 26% ? 33%

* Basic Earnings/Headline Earnings : R124 million ? R133 million - R89 million - 39% ? 49%

* Basic Earnings/Headline Earnings per share : 46 ? 49 cents - 35 cents - 31% ? 40%

* Profit after tax: R128 million ? R134 million - R89 million - 44% ? 51%



Shareholders are advised that the results for the six months ended 31 December 2015 are scheduled to be released on SENS on 9 March 2016 and to be presented in Cape Town on the 9th of March 2016 and Johannesburg on the 10th of March 2016.
19-Nov-2015
(Official Notice)
13-Nov-2015
(Official Notice)
Ascendis shareholders are advised that at the Third Annual General Meeting of members held on Thursday, 12th November 2015, all the ordinary and special resolutions as proposed in the Notice of the Annual General Meeting were approved by the requisite majority of members.

*Total number of shares that could be voted at meeting: 100% - 270 232 494

*Total number of shares present/represented including proxies at meeting: 74.51% - 201 341 399

*Total number of members present/presented by representation: 59
14-Oct-2015
(Official Notice)
Shareholders are advised that the Integrated Annual Report for the year ended 30 June 2015, including summarised consolidated financial statements for the same period, has been posted to shareholders and is available on the company?s website with effect from Wednesday, 14 October 2015 at: http://www.ascendis.co.za/wp-content/uploads/2015/09/JOB07631_Ascendis_AR_2015_v2.pdf



The full audited annual financial statements are also available on the company?s website at: http://www.ascendis.co.za/wp-content/uploads/2015/09/Final-AFS-signed-20150928.pdf



Copies of the annual general meeting notice, the summarised audited financial statements, and the complete annual financial statements as at 30 June 2015 are obtainable from:

? the company?s registered office: 22 Sloane Street, Bryanston, Gauteng, 2191; or

? by email to: info@ascendis.co.za



No change statement

The annual financial statements referred to herein contain no modification relative to the audited results that were published on 9 September 2015 through the JSE?s news service, SENS, and in the press on 10 September 2015. Ascendis? results and the annual financial statements have been audited by PricewaterhouseCoopers Inc. whose unqualified reports are available for inspection at the company?s registered office.



Notice of the third annual general meeting

Members are advised that the company?s third annual general meeting has been convened for 09:00 on Thursday, 12 November 2015, at Block A, Silverwood, Steenberg Office Park, Silverwood Close, Tokai, Cape Town, 7 9 4 5 to transact the business stated in the notice of the meeting.



Participation in the annual general meeting will be facilitated by webcasting as well. Relevant details appear in the notice of the meeting.



The Notice to the third annual general meeting is also available on the company?s website at: http://www.ascendis.co.za/wp-content/uploads/2015/08/JOB07651_Ascendis_Notice_of_AGM_FA.pdf
09-Sep-2015
(C)
Revenue came in higher at R2.8 billion (R1.6 billion). Gross profit was calculated at R1.2 billion (R728 million). Operating profit increased to R362.2 million (R213.8 million). Profit attributable to owners of the parent was recorded at R209.8 million (R136.2 million). Headline earnings per share from continued operations rose to 80.24cps (64.34cps)



Dividend

The board of directors has approved a final gross ordinary dividend of 11cps, following the interim dividend of 8 cents, which makes a total dividend of 19 cents for the financial year ending 30 June 2015 (2014: 15cps).



Outlook

The group's acquisitive growth strategy continues to gain momentum. Internationally the strategy will focus on the acquisition of platform companies for all business units and mainly target opportunities in Australia, Europe, USA and Africa. In South Africa, the group is in negotiations for bolt-on acquisitions across all divisions. Operationally the group's priorities are to improve gross margins through increased local and in-house production, strict cost control and focus on efficiencies, to accelerate the growth in export sales and continue new product development and innovation.



The integration of The Scientific Group into the Medical Devices division will enable management to create economies of scale between the three complementary medical businesses in the group. The Farmalider acquisition will create many synergies through cross border licensing of dossiers and opening new markets and customers for Farmalider and the Ascendis Pharma division.



01-Sep-2015
(Official Notice)
Ascendis shareholders are hereby advised that the company?s financial results for the twelve months ended 30 June 2015 are expected to be more than 20% higher than the previous corresponding period.



The table below illustrates the ranges anticipated against the comparative period

Years ended 30 June 2015 and 30 June 2014, % increase

*Normalised Headline Earnings -- R237m ? R248m; R153m; 55% ? 62%

*Normalised Headline Earnings per share -- 90 ? 95 cent; 72 cents; 25% ? 32%

*Basic Earnings/Headline Earnings -- R201m ? R211m; R136m; 48% ? 55%

*Basic Earnings/Headline earnings per share -- 78 ? 81 cents; 64 cents; 22% ? 27%

*Operating profit R353m ? R368m; R214m; 65% ? 72%



Shareholders are advised that the results for the twelve months ended 30 June 2015 are scheduled to be released on SENS on 9 September 2015 and to be presented in Cape Town on the 9th and Johannesburg on the 10th of September 2015.
27-Aug-2015
(Official Notice)
Ascendis announced the appointment of Kieron Futter as an executive director and CFO of Ascendis with effective from 1st October 2015, this appointment being on a temporary basis as per s.68(3) of the Companies Act No.71 of 2008 and s.26.4.1.1 of the Company?s Memorandum of Incorporation, pending his election at the Ascendis? AGM scheduled to take place on 12 th November 2015.
03-Aug-2015
(Official Notice)
09-Jun-2015
(Official Notice)
Ascendis announced the appointment of Cliff Sampson as acting managing director of the company with effect from 1 July 2015. Cliff will assume the responsibility as managing director (?MD?) of the South African operations, reporting to Dr Karsten Wellner, the Ascendis Group chief executive officer. Cliff?s formal appointment as executive director to the board will be proposed for approval to shareholders at the company?s next annual general meeting to be held during November 2015, as required in terms of the company?s Memorandum of Incorporation.
24-Apr-2015
(Official Notice)
In compliance with paragraph 3.59 of the Listings Requirements of the JSE Ltd., shareholders are advised that Robbie Taylor has resigned as chief financial officer (?CFO?) and director of Ascendis and will be leaving Ascendis with effect from 30 June 2015.



Management plans to start the selection process for a new CFO immediately. Owing to the Group?s increasing presence in Africa and its international growth ambitions the board has determined that the new CFO will be based at the Group?s operations head office in Johannesburg.



Johan van Schalkwyk who is currently a director of Ascendis? major shareholder and investment group Coast2Coast, has been appointed as interim CFO with immediate effect until a new CFO has been appointed. Johan is a chartered accountant having placed 1st in the SAICA Board exam. He holds a Masters degree in Management Studies from the University of Cambridge. He has extensive financial, commercial and international experience gained from his experience at Deloitte and McKinsey Inc., with 6 years spent at both Rand Merchant Bank and Standard Chartered. He has played a leading role in several of the M-A transactions undertaken by Ascendis.
11-Mar-2015
(C)
Revenue from continuing operations for the interim period increased to R1.3 billion (R661.9 million), while gross profit was higher at R597.6 million (R305.1 miilion). Operating profit rose to R161 million (R87.6 million), and profit attributable to owners of the parent for continuing operations grew to R88.5 million (R53.9 million), and headline earnings per share from continuing operations came in at 35.5cps (29.2cps).



Dividends

The board of directors has approved an interim gross ordinary dividend of 8cps (2014: nil). The source of the dividend will be from distributable reserves and paid in cash.



Outlook

The group's priority is to deliver on its organic and acquisitive growth strategies. Ascendis owns a portfolio of leading South African brands and plans to maximise the export potential of these brands and to focus on offshore acquisitions to grow its international operations. The group is currently considering the pursuit of international acquisitions for the Pharma-Med platform. Potential bolt-on acquisitions for the Consumer Brands and Phyto-Vet divisions are also being evaluated. The key operational deliverables for the remainder of the financial year include the integration of The Scientific Group; continued new product development and innovation; extracting vertical and horizontal synergies; growing export markets; managing the impact of foreign exchange fluctuations on revenue and profitability; and simplifying its group structure and realising cost synergies across the value chain and between its divisions. The ongoing focus on these growth strategies is expected to result in continued value creation for shareholders.





06-Mar-2015
(Official Notice)
Ascendis shareholders are hereby advised that the company?s financial results for the six months ended 31 December 2014 are expected to be more than 20% higher than the previous corresponding period.



The table below illustrates the ranges anticipated against the comparative period:

6 months ended 31 December 2014, 6 months ended 31 December 2013 and % increase

*Normalised Earnings -- R106 ? R110m; R62m; 71 ? 77%

*Normalised Headline Earnings per share -- 42.5 ? 44.0 cents; 33.4 cents; 27 ? 32%

*Basic Earnings -- R86 ? 90m; R54m; 59 ? 67%

*Basic Earnings per share -- 34.7 ? 36.2 cents; 29.2 cents; 19 ? 24%

*Headline Earnings -- R86 ? 90m; R54m; 59 ? 67%

*Headline Earnings per share -- 34.7 ? 36.2 cents; 29.2 cents; 19 ? 24%



Shareholders are advised that the results for the six months ended 31 December 2014 are scheduled to be released on SENS on 11 March 2015.
02-Mar-2015
(Official Notice)
Ascendis shareholders are referred to the SENS announcement dated 27 October 2014 advising of Ascendis entering into an agreement with the shareholders of SG to acquire 100% of the diagnostics business of SG (?the Acquisition?), subject to the fulfilment of certain conditions precedent, including receipt of approval from the South African Competition Commission as well as the Competition Commissions of certain other African jurisdictions (?Competition Authorities?). The Company?s board of directors is pleased to announce that the final outstanding condition precedent, namely the approval from the Competition Authorities, has been granted which accordingly renders the Acquisition unconditional.
27-Nov-2014
(Official Notice)
14-Nov-2014
(Official Notice)
Ascendis shareholders are advised that at the Second Annual General Meeting of members held on Thursday, 13th November 2014, all the ordinary and special resolutions as proposed in the Notice of the Annual General Meeting were approved by the requisite majority of members.



07-Nov-2014
(Official Notice)
27-Oct-2014
(Official Notice)
16-Oct-2014
(Official Notice)
The company's 2014 summary financial review presented in a separate booklet containing the company's summarized audited consolidated financial statements for the year ended 30 June 2014, has been distributed by the close of business on Tuesday, 30 September 2014. The full audited annual financial statements are also available on the company's website, at

http://www.ascendis.co.za/wr-pdv/wp-content/uploads/2014/09/AH-Group-final-signed-financial- statements.pdf



Copies of the annual general meeting notice including the summarized audited financial statements and the complete annual financial statements as at 30 June 2014 are obtainable from:

* the company's registered office: 22 Sloane Street, Bryanston, Gauteng, 2191; or

* by email to: info@ascendis.co.za



The annual financial statements referred to herein contain no modification relative to the audited results that were published on 9 September 2014 through the JSE's news service, SENS, and in the press on 10 September 2014. Ascendis' results and the annual financial statements have been audited by PricewaterhouseCoopers Inc. whose unqualified reports are available for inspection at the company's registered office.



Notice of annual general meeting

Members are advised that the annual general meeting has been convened for 09:00 on Thursday, 13 November 2014, at Kirstenbosch National Botanical Garden, Rhodes Avenue, Newlands, 7700 to transact the business stated in the notice of the meeting.



Participation in the annual general meeting will be facilitated by webcasting as well. Relevant details appear in the notice of the meeting.
29-Sep-2014
(Official Notice)
15-Sep-2014
(Official Notice)
09-Sep-2014
(C)
02-Sep-2014
(Official Notice)
Ascendis expects to announce that statutory headline earnings per share and earnings per share for the full year ended 30 June 2014 are expected to be between 64 - 67 cents per share compared to the forecast information of 55 cents contained in the pre-listing statement. The Company's audited results for the year ended 30 June 2014 are expected to be published on SENS on or about 9 September 2014.
25-Aug-2014
(Official Notice)
Ascendis shareholders are referred to the SENS announcement dated 12 June 2014, advising of Ascendis entering into an agreement with the shareholders of RCA to acquire 100% of the issued ordinary share capital of RCA ("the Acquisition"), subject to the fulfilment of certain conditions precedent, including receipt of approval from the South African Competition Commission ("Competition Authorities"). The Company's board of directors announced that as at 25 August 2014 all outstanding conditions precedent have been fulfilled and payment has been effected. Accordingly the Acquisition is unconditional.
11-Aug-2014
(Official Notice)
26-Jun-2014
(Official Notice)
Highlights of the BEE deal:

*The Coast2Coast Investments (Pty) Ltd. ("C2C") directors dealing (the "Transaction") concluded with the MIC Investment Holdings (Pty) Ltd. will increase the BEE ownership in Ascendis from [R165 million] currently to a potential [R365m] over a three year period, excluding any further investment or disposal by existing or new BEE shareholders.

*BEE remains a strategic imperative in the ongoing transformation of Ascendis and is essential for a listed company operating in the private and public healthcare sector in South Africa.

*MIC (Mineworkers Investment Company) is a highly respected BBBEE partner and is committed to contributing meaningfully to the continued success and transformation of Ascendis.

*This transaction will have no earnings dilution or cost for Ascendis shareholders (excluding C2C).



Transaction overview

The Transaction involves C2C and does not initially incorporate Ascendis (refer separately to the C2C directors' dealing announcement). Indirectly, and over a three year period from the date of the Transaction, MIC becomes a meaningful Ascendis BEE shareholder, hence this communication to shareholders.



C2C (in which Gary Shayne and Crispian Dillon have a 100% beneficial interest), does not form part of the Ascendis group of companies, and has entered into a separate agreement (the "Debenture Agreement") with the MIC Investment Holdings, dated 30 June 2014, whereby C2C has issued the MIC Investment Holdings a fixed coupon, convertible, redeemable debenture at a face value of R200 million, convertible in three tranches into Ascendis shares which are owned by C2C:

*Tranche 1: R30 million mandatory convertible debenture at a fixed coupon rate of 15%.

*Tranche 2: R30 million optional convertible debenture at a fixed coupon rate of 15%.

*Tranche 3: R140 million optional convertible debenture at a fixed coupon rate of 13%.



The coupon and the cost of the discount applied to the respective volume weighted average share price of Ascendis, upon the annual conversion of the convertible debenture, will be borne entirely by C2C.
12-Jun-2014
(Official Notice)
11-Jun-2014
(Official Notice)
In response to the Business Day article published on 10 June 2014, Ascendis hereby releases this corrective announcement which serves to clarify the statement pertaining to the portion of Ascendis? turnover affected by the new CMS regulations.



It should be duly noted that Ascendis? Consumer Brands Division represents approximately 40% of the Company?s [annualised] turnover with Solal representing approximately 8% of Ascendis? annualised turnover. Up to a maximum of 20% of Solal's sales are potentially impacted by the CMS regulations which therefore amounts to 1,6% of Ascendis' annualised turnover being potentially impacted by the regulations and not the 9% as reported within the article. Ascendis continues to perform well with robust organic growth, as previously reported within the interim results announcement released on 3 March 2014.
02-Jun-2014
(Official Notice)
Ascendis shareholders are referred to the SENS announcement dated 27 February 2014, advising of Ascendis entering into an agreement with the shareholders of Pharma Natura to acquire 100% of the issued ordinary share capital of Pharma Natura ("the Acquisition"), subject to the fulfilment of certain conditions precedent, including receipt of approval from the South African Competition Commission ("Competition Authorities").



The Company's board of directors is pleased to announce that with effect from 30 May 2014 all of the conditions precedent to the Acquisition (which includes the required approval by the Competition Authorities) have been fulfilled or waived and the Acquisition is accordingly unconditional.
29-Apr-2014
(Official Notice)
Shareholders are advised that Ascendis has appointed Investec Bank Ltd as sponsor to the company with effect from 1 May 2014.

28-Mar-2014
(Official Notice)
In accordance with paragraph 2.6A of the JSE Listings Requirements, shareholders are advised that Nedbank Capital will no longer be acting in the capacity as Sponsor to the company with effect from 1 May 2014.
03-Mar-2014
(Official Notice)
Shareholders are advised that following a promotion within the group, Mr P van Niekerk has resigned as company secretary with immediate effect.



Further to the above, Mr A Sims, previously the financial director of a group subsidiary, has been appointed as company secretary of Ascendis with immediate effect.
03-Mar-2014
(C)
Ascendis released their maiden interim results, therefore there are no comparable figures. Revenue for the interim period came in at R661.9 million while gross profit was R305.1 million. EBITDA was recorded at R101.9 million, profit attributable to owners of the parent was R53.9 million, and headline earnings per share came in at 29cps.



Dividends

No dividends have been declared by Ascendis for the six months ending 31 December 2013.



Outlook

Ascendis has a portfolio of resilient, well-established brands which offer both pricing leverage and strong export potential which positions it well in the face of a tough consumer economy, a more stringent regulatory environment and a depreciating currency. The brands in the Consumer Brands and Phyto-Vet divisions are mostly aimed at higher LSM consumers making the business more resilient in the face of weaker economic conditions. The brands in the pharmaceutical sector of the Pharma-Med division focus more on the lower LSM consumer and will benefit from government's focus on making medicines more affordable and accessible, and the National Health Insurance implementation.



The group is well positioned to accelerate the growth in its export operations, with keen interest from offshore distributors for several brands in the Ascendis stable which are not yet exported. The group has a healthy acquisition pipeline and is currently evaluating projects in all divisions. A key focus for the remainder of the financial year will be on continuing to deliver organic growth, integrating acquisitions and extracting synergies both within and across the operating divisions.



The directors remain confident of achieving the pre-listing earnings forecast of R124 million after tax (after capitalising listing fees) for the 2014 financial year, based on the existing business at the time of listing. In addition there will be further benefits from post listing acquisitions.
27-Feb-2014
(Official Notice)
21-Jan-2014
(Official Notice)
Ascendis shareholders are referred to the SENS announcement dated 25 November 2013, advising of Ascendis entering into an agreement with the shareholders of Surgical Innovations to acquire 100% of the issued ordinary share capital of Surgical Innovations ("the Acquisition"), subject to the fulfilment of certain conditions precedent, including receipt of approval from the South African Competition Commission ("Competition Authorities").



The company's board of directors is pleased to announce that the Competition Authorities granted the required approval on 21 January 2014, being the final outstanding condition precedent, which accordingly renders the Acquisition unconditional.
25-Nov-2013
(Official Notice)
As the detailed terms of the acquisition of Surgical Innovations (Pty) Ltd. have been disclosed, shareholders are no longer required to exercise caution when dealing in the company's securities.
25-Nov-2013
(Official Notice)
25-Nov-2013
(Official Notice)
22-Nov-2013
(Official Notice)
If the proposed acquisition is successfully concluded it may have a material effect on the price of the company's securities. Accordingly, shareholders are advised to exercise caution when dealing in the company's securities until a full announcement is made.
22-Nov-2013
(Official Notice)
Shareholders were advised that the company is in advanced negotiations to acquire a medical devices business ("the Proposed Acquisition"). The Proposed Acquisition is intended to become an essential part of the group's Pharma-Med Division. This business has key agencies for surgical and other medical equipment which positions Ascendis well to service hospitals, clinics and government tenders. Key contributions of the Proposed Acquisition include:

*the importation and distribution of specialist medical devices focused on the areas of general surgery, gynaecology, urology, ear, nose and throat, cardiology and radiology; and

*the marketing of devices in a South African agent function, on an exclusive basis, for international brands of high value-add, niche consumable medical devices.
15-Mar-2018
(X)
Ascendis Health is a South African-based global health and care company which owns a portfolio of market-leading brands for humans, plants and animals.



The group?s strategy is to complement organic growth in the health and care markets by acquiring bolt-on companies in South Africa, acquiring international platform and complementary businesses, and extracting synergies from these acquisitions.



The brands are housed across the Pharma-Med, Consumer Brands and Phyto-Vet divisions, with revenue diversified across products, channels, geographic regions and currencies.


Send e-mail to for any enquiries or see Contact Details for phone numbers
Home   •   Terms & conditions   •   PAIA   •   Privacy Policy   •   Security Notice   •   Contact Details
Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics. The calculation/derivation may include underlying JSE data.
© 2018 SHARENET (PTY) Ltd, Cape Town, South Africa
Best in 800x600 with IE6 or Mozilla Firefox